Short vs Long Arm Cast for Distal Radius Fractures: the Verona Trial (SLA-Ver)

September 27, 2020 updated by: Tommaso Maluta, Azienda Ospedaliera Universitaria Integrata Verona

Short vs Long Arm Cast for Distal Radius Fractures: the Verona Trial. Randomized Clinical Trial to Assess the Efficacy of Short Arm Cast Versus Long Arm Cast in Conservative Management of Distal Radius Fractures

This study prospectively compares the performance of an above-elbow cast (long arm cast) and a below-elbow cast (short arm cast) to maintain reduction in conservatively managed distal radius fractures.

Study Overview

Status

Completed

Detailed Description

The choice of cast length in conservative management of distal radius fractures still represents a much debated controversy. Classic teaching was to immobilize the elbow to reduce risk of secondary displacement; however, short arm casts are felt to be equally effective with less complications and higher patient comfort. There is currently no conclusive evidence for or against immobilization of the elbow in patients treated with cast immobilization.

Study Type

Interventional

Enrollment (Actual)

353

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Verona, Italy, 37126
        • Ospedale Civile Maggiore Borgo Trento

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of distal radius fracture
  • Indication to conservative treatment
  • Need for manipulation to reduce fracture

Exclusion Criteria:

  • Open fractures
  • Existence of any skin lesion or wound that would impair cast treatment
  • Neurovascular deficits
  • Bilateral fractures
  • Association with any other fracture of the homolateral arm

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Short arm cast
Patient treated with below-elbow cast
Application of a below-elbow cast
Other Names:
  • below-elbow cast
  • antebrachio-metacarpal cast
Active Comparator: Long arm cast
Patients treated with above-elbow cast
Application of an above-elbow cast
Other Names:
  • above-elbow cast
  • brachio-metacarpal cast

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary displacement ratio
Time Frame: 35 days
Percentage of fractures that displace during treatment as subjectively assessed on radiographs by investigators.
35 days
Variation of radial length
Time Frame: 35 days
Difference between radial length values as objectively measured on postreduction radiographs and endtreatment radiographs.
35 days
Variation of radial inclination
Time Frame: 35 days
Difference between radial inclination values as objectively measured on postreduction radiographs and endtreatment radiographs.
35 days
Variation of volar tilt
Time Frame: 35 days
Difference between volar tilt vaues as objectively measured on postreduction radiographs and endtreatment radiographs.
35 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Post-treatment elbow range of motion (ROM)
Time Frame: 35 days
Degrees of extension, flexion, pronation and supination of the elbow measured at the end of the treatment.
35 days
DASH score
Time Frame: 35 days
Disability of Arm, Shoulder and Hand score measured at the end of the treatment relating to patient's comfort during treatment.
35 days
SF-12
Time Frame: 35 days
Short Form 12 health questionnaire administered at the end of the treatment relating to patient's quality of life during treatment.
35 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Tommaso Maluta, MD, Azienda Ospedaliera Universitaria Integrata Verona
  • Principal Investigator: Giovanni Dib, MD, Azienda Ospedaliera Universitaria Integrata Verona
  • Principal Investigator: Matteo Cengarle, MD, Azienda Ospedaliera Universitaria Integrata Verona
  • Principal Investigator: Alice Bernasconi, DR, Azienda Ospedaliera Universitaria Integrata Verona
  • Principal Investigator: Franco Lavini, MD, Azienda Ospedaliera Universitaria Integrata Verona
  • Study Chair: Andrea Scalvi, MD, Azienda Ospedaliera Universitaria Integrata Verona
  • Study Chair: Bruno Magnan, MD, Azienda Ospedaliera Universitaria Integrata Verona

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 15, 2017

Primary Completion (Actual)

February 13, 2020

Study Completion (Actual)

March 28, 2020

Study Registration Dates

First Submitted

March 11, 2018

First Submitted That Met QC Criteria

March 15, 2018

First Posted (Actual)

March 16, 2018

Study Record Updates

Last Update Posted (Actual)

September 29, 2020

Last Update Submitted That Met QC Criteria

September 27, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 1165CESC
  • 1166CESC (Registry Identifier: Comitato Etico per la sperimentazione clinica delle province di Verona e Rovigo)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Radius Fracture Distal

Clinical Trials on Short arm cast

3
Subscribe